May 21, 2020 / 09:30PM GMT
Operator
Greetings, and welcome to the Navidea Biopharmaceuticals Results of Second Interim Analysis of Phase IIb Study in Rheumatoid Arthritis. (Operator Instructions) Please note that this conference is being recorded. I will now turn the conference over to our host, Jed Latkin, Chief Executive Officer.
Jed A. Latkin - Navidea Biopharmaceuticals, Inc. - CEO, COO, CFO & Director
That's a little bit of a reverb there. Sorry about that, guys.
Good afternoon. Okay. Sorry. Are we live? Okay.
Good afternoon, and welcome, everyone, to today's conference call, where we will be covering the second interim data analysis from the company's ongoing Phase IIb trial in rheumatoid arthritis. I'm Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. Following our prepared remarks, we will open up the conference call to a question-and-answer session. With me on our call today is our Chief Medical Officer, Dr. Mike Rosol.
Before we begin our formal remarks, I just want to quickly go through the safe harbor. I would like to remind everyone
Navidea Biopharmaceuticals, Inc. - Special Call Transcript
May 22, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers